Carnes, Megan Ulmer
Quach, Bryan C. http://orcid.org/0000-0002-1094-3104
Zhou, Linran
Han, Shizhong
Tao, Ran
Mandal, Meisha
Deep-Soboslay, Amy
Marks, Jesse A.
Page, Grier P. http://orcid.org/0000-0003-2582-3786
Maher, Brion S.
Jaffe, Andrew E.
Won, Hyejung http://orcid.org/0000-0003-3651-0566
Bierut, Laura J. http://orcid.org/0000-0002-9952-4810
Hyde, Thomas M. http://orcid.org/0000-0002-8746-3037
Kleinman, Joel E. http://orcid.org/0000-0002-4210-6052
Johnson, Eric O. http://orcid.org/0000-0002-8870-1949
Hancock, Dana B. http://orcid.org/0000-0003-2240-3604
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R21 DA051921, R01 DA051913)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Article History
Received: 30 November 2023
Revised: 19 April 2024
Accepted: 6 May 2024
First Online: 4 June 2024
COMPETING INTERESTS
: MUC: None. BCQ: None. LZ: None. SH: None. RT: None. MM: None. AD-S: None. JAM: None. GPP: None. BSM: None. AEJ: AEJ is currently an employee and shareholder of Neumora Therapeutics; this connection is unrelated to the contents of this manuscript. HW: None. LJB: LJB is listed as an inventor on U.S. Patent 8,080,371,“Markers for Addiction,” covering the use of specific genetic variants in determining the diagnosis, prognosis, and treatment of addiction. TMH: None. JEK: JEK is a paid consultant for Merck as member of a data monitoring committee. EOJ: None. DBH: None.